Castration-resistant prostate cancer
Conditions
Interventions
Chemotherapy: Docetaxel 70mg/m2 div. every 4 weeks. Predonisolone 10mg/day p.o. daily.
Hormonal therapy: Ethynil estradiol 1.0mg/day p.o. daily.
Sponsors
Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed as prostate cancer pathologically at the initial treatment. 2)Clinical any T any N any M prostate cancer patient treated by androgen deprivation therapy prior to this trial. 3)Cancer relapse or disease progression must be confirmed after androgen deprivation therapy. 4)Age over 20 years old 5)4) Patients must be at a score level of 0-1 of performance status (PS) (ECOG). 6)Major organ function must be conserved before registration. 7)Written informed consent must be obtained from patients.
Exclusion criteria
Exclusion criteria: 1)Patients who received cytotxic-chemotherapy prior to this trial. 2)Patients who received estrogen therapy prior to this trial. 3)Patients who received radiation therapy to primary cancer site within 3 monthsprior to this trial. 4)Patients who diagnosed pulmonary fibrosis or interstitial pneumonitis. 5)Patients who have a history of acute myocardial infarction within 6 months. 6)Severe cormobidity (DM, heart disease, liver dysfunction etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to treatment failure | — |
Countries
Japan
Contacts
Public ContactKosuke Takehara
Nagasaki University Graduate School of Biomedical Sciences Department of Nephro-Urology
Outcome results
None listed